LA JOLLA, Calif., April 16, 2013 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCBB:INNV) today announced that Dr. Bassam Damaj, Ph.D., Chief Executive Officer, will present at the BIO Business Forum in Chicago on Tuesday, April 23 at 2:30 p.m. CDT.
"The BIO Business Forum is an outstanding venue for presenting Innovus Pharma as a Company and specifically our product portfolio," said Dr. Damaj. "In addition to our presentation, the Forum provides an opportunity for one-on-one business development meetings and interaction with industry leaders through the Forum Partnering program."
The BIO Business Forum is part of the BIO International Conference, which is being held April 22-26, 2013 at McCormick Place. The conference is sponsored and hosted by the Biotechnology Industry Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
Innovus Pharma, headquartered in La Jolla, is a global healthcare company that delivers innovative and uniquely presented and packaged health solutions through its prescription medicines and consumer and health products.
Innovus is an emerging pharmaceutical company that develops, in-licenses, acquires and markets proprietary pharmaceutical products. Innovus has a robust pipeline that will be positioned for unique packaging and presentation, especially for ease of use and patient compliance, with a focus on dermatology, autoimmune disease, sexual dysfunction, and respiratory disease.
Innovus Pharma has been building a robust pipeline, with a wide range of approved products such as its APEAZ™ line of products. The APEAZ™ brand will include the arthritis cream, sport cream, acne control cream, hemorrhoids cream and Zinx cough/cold lozenge medicine. In addition to its consumer health product line, the Company is building its prescription product pipeline including its Atopic dermatitis and seborrheic dermatitis topical product. Specific product candidates range across each phase of development, such as its VAP-1 program for psoriasis and dermatitis
Innovus has also signed a binding term sheet for the acquisition of CIRCUMserum™, a product for increasing sensitivity to the skin of the penis. In a use study done after the product was launched in 2012 in the U.S., 80% of regular users reported heightened sensations and greater sexual satisfaction.
In order to commercialize the Innovus pipeline, the company plans to in-license or acquire products for the Middle East and North Africa (MINA) region and the United States.
Damaj took the reins of Innovus as CEO in January, 2013. In his previous position at Apricus Biosciences, the market cap of Apricus grew from $17 million to more than $100 million. During Damaj's tenure at Apricus, partnerships were signed with companies such as Abbott, Sandoz, and Takeda.
For more information, go to: www.innovuspharma.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may be considered to be "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that may individually or mutually impact the matters described in this release for a variety of reasons, many of which are outside the control of Innovus Pharma. These risks and uncertainties include, but are not limited to Innovus Pharma's ability to negotiate the definitive agreements for the acquisition of CIRCUMserum and the line of prescription products in dermatitis on terms and conditions satisfactory to it, Innovus Pharma's ability to raise sufficient capital to fund its operations and growth strategy in the long term, Innovus Pharma's ability to achieve its development, regulatory, commercialization and financial goals for its existing products, its ability to acquire additional products, and its ability to achieve development, regulatory, commercialization and financial goals for such additional products. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K and other filings made with the SEC. Copies of these reports are available from the SEC's website or the "Investors" section of Innovus Pharma's website at innovuspharma.com.